Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
Retrieved on:
Saturday, May 20, 2023
Well, CSS, Functional, Heart, NYHA, Research and development, Clinical study design, Week, Cohort, LVEF, Health status of Asian Americans, Angina, Hypertrophy, Oregon Health and Science University Center for Women's Health, Dizziness, Cytokinetics, Patient, N-terminal prohormone of brain natriuretic peptide, Cardiology, Heart failure, SE, European Society for Primary Immunodeficiencies, International Congress on Tuberculosis, Pharmaceutical industry, KCCQ, HCM
SOUTH SAN FRANCISCO, May 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), a Phase 2, open-label clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM), were presented in a Late Breaking Clinical Trial session at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023.
Key Points:
- We look forward to advancing aficamten into a Phase 3 clinical trial in patients with nHCM which is expected to begin in the second half of this year.”
The new data from Cohort 4, presented today by Ahmad Masri, M.D. - At 10 weeks, treatment with aficamten was associated with an average improvement in KCCQ-CSS of 10.6 points (p
- Additionally, 56% of patients demonstrated improvement of ≥1 New York Heart Association (NYHA) Functional Class (p = 0.011) (Figure 2).
- Four patients (9.8%) had serious adverse events, including one previously reported death, and none were attributed to aficamten.